Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer by She, Qing-Bai et al.
RESEARCH ARTICLE Open Access
Integrated molecular pathway analysis
informs a synergistic combination therapy
targeting PTEN/PI3K and EGFR pathways
for basal-like breast cancer
Qing-Bai She1,2,3, Sofia K. Gruvberger-Saal4,5, Matthew Maurer6,7, Yilun Chen4, Mervi Jumppanen8, Tao Su6,
Meaghan Dendy5, Ying-Ka Ingar Lau6, Lorenzo Memeo9, Hugo M. Horlings10, Marc J. van de Vijver11, Jorma Isola12,
Hanina Hibshoosh6,13, Neal Rosen1, Ramon Parsons5,7,13,14 and Lao H. Saal4,5,15*
Abstract
Background: The basal-like breast cancer (BLBC) subtype is characterized by positive staining for basal mammary
epithelial cytokeratin markers, lack of hormone receptor and HER2 expression, and poor prognosis with currently no
approved molecularly-targeted therapies. The oncogenic signaling pathways driving basal-like tumorigenesis are
not fully elucidated.
Methods: One hundred sixteen unselected breast tumors were subjected to integrated analysis of phosphoinositide
3-kinase (PI3K) pathway related molecular aberrations by immunohistochemistry, mutation analysis, and gene expression
profiling. Incidence and relationships between molecular biomarkers were characterized. Findings for select biomarkers
were validated in an independent series. Synergistic cell killing in vitro and in vivo tumor therapy was investigated in
breast cancer cell lines and mouse xenograft models, respectively.
Results: Sixty-four % of cases had an oncogenic alteration to PIK3CA, PTEN, or INPP4B; when including upstream kinases
HER2 and EGFR, 75 % of cases had one or more aberration including 97 % of estrogen receptor (ER)-negative tumors.
PTEN-loss was significantly associated to stathmin and EGFR overexpression, positivity for the BLBC markers cytokeratin
5/14, and the BLBC molecular subtype by gene expression profiling, informing a potential therapeutic combination
targeting these pathways in BLBC. Combination treatment of BLBC cell lines with the EGFR-inhibitor gefitinib plus
the PI3K pathway inhibitor LY294002 was synergistic, and correspondingly, in an in vivo BLBC xenograft mouse
model, gefitinib plus PI3K-inhibitor PWT-458 was more effective than either monotherapy and caused tumor regression.
Conclusions: Our study emphasizes the importance of PI3K/PTEN pathway activity in ER-negative and basal-like breast
cancer and supports the future clinical evaluation of combining EGFR and PI3K pathway inhibitors for the treatment
of BLBC.
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Background
Breast cancer (BC) is comprised of several molecular
subtypes with varied biological and clinical characteris-
tics. Of these, the four most discernible subtypes by gene
expression profiling include the two estrogen-receptor
(ER)-positive subtypes, luminal A and B which are cha-
racterized by low and high proliferation, respectively; the
HER2 subtype characterized by overexpression of genes
in the HER2 (ERBB2) amplicon; and the basal-like BC
(BLBC) subtype characterized by expression of basally-
oriented mammary epithelial cell markers such as cyto-
keratins 5 and 14 (CK5/14), lack of hormone receptors
and HER2 expression (“triple-negative”), and high gen-
omic instability [1]. Although therapies that target estro-
gen pathways or the HER2 receptor are part of the
standard armamentarium in clinical use today, currently
no specific drugs that target the basal-like subtype are
approved. The basal-like subtype also has a particularly
poor prognosis, underscoring the need for improved
therapeutic options for women with this class of cancer.
Recent studies point to the importance of the phos-
phatidylinositol 3-kinase (PI3K) and phosphatase and
tensin homolog deleted on chromosome ten (PTEN)
oncogene/tumor suppressor axis in breast tumorigenesis.
The PIK3CA oncogene, which encodes the PI3K p110
catalytic subunit alpha and phosphorylates phos-
phatidylinositol 3,4-bisphosphate (PIP2) to PIP3, has
been shown to have activating mutations in approxi-
mately 30 % of BCs, primarily within ER-positive cases
[2–6]. Although the tumor suppressor PTEN, a lipid
phosphatase acting in direct enzymatic opposition to
PI3K, is infrequently inactivated by mutations in spor-
adic BC (5 %), PTEN protein expression is significantly
reduced in ~25 % breast tumors, more commonly in ER-
negative cancer and in particular within BLBC, and
rarely coinciding with PIK3CA mutation [2, 7]. PTEN is
also frequently grossly mutated in BRCA1-hereditary BC,
a group of tumors that usually exhibit the basal-like
phenotype [7, 8], and new nuclear roles for PTEN in main-
taining genome stability have been identified. Another
lipid phosphatase, inositol polyphosphate 4-phosphatase
type II (INPP4B), has recently been shown to have poten-
tial tumor suppressor activity [9, 10]. The tumor supp-
ressive role of INPP4B is linked to its function in
dephosphorylating PIP2, depleting this substrate of PI3K,
and accordingly loss of INPP4B leads to increased PIP3-
mediated signaling to AKT and is associated with poor
outcome (reviewed in [11]). Additionally, numerous up-
stream receptor tyrosine kinases (RTKs), such as HER2
and EGFR, have been shown to activate PI3K pathway sig-
naling [12, 13], and EGFR also potently signals through
the RAS/RAF/MEK (MAPK) pathway [14]. Constitutive
activation of PI3K pathway by PTEN mutation/loss or
PIK3CA mutation could render tumor cells independent
of RTKs for malignant transformation and maintenance,
which leads to resistance to HER2-targeted therapies in
BC and EGFR-targeted therapies in glioma [15–20].
To understand the natural history of PI3K pathway
activating alterations and relate them to BC subtypes
and other molecular and genetic alterations, we have
performed an extensive analysis of pathway biomarker
lesions in an unselected cohort of breast tumors. We
examined the incidence of pathway lesions, and disco-
vered novel associations to standard clinicopathological
markers and to BC subtypes including the frequent coin-
cident loss of PTEN and overexpression of EGFR in
BLBC. We then assessed whether a combination thera-
peutic strategy targeting both the PTEN/PI3K pathway
and EGFR would be more effective than monotherapy
using in vitro and in vivo models.
Methods
Human breast cancer samples
For 116 primary BC patients consented and treated at
Columbia University Herbert Irving Comprehensive Can-
cer Center/New York-Presbyterian Hospital, formalin-fixed
paraffin-embedded (FFPE) tumor blocks and DNA and
total RNA isolated from corresponding frozen tumor spec-
imens were obtained (Columbia cohort; Table 1). All sam-
ples were blinded and anonymized and obtained with
ethics approval from Columbia University’s Institutional
Review Board. This unselected cohort is comprised of pa-
tients diagnosed between 1986 and 2003 with all stages of
BC and the patients received standard of care therapies.
FFPE tissue microarrays for an independent series of 295
consecutive women with stage I and II breast cancer
treated at the Netherlands Cancer Institute (NKI) was
obtained [21, 22].
Tissue microarray construction
Tissue microarrays (TMAs) were constructed for the
Columbia cohort by the Experimental Molecular Pathology
Core Facility of the Herbert Irving Comprehensive Cancer
Center utilizing a Manual Tissue Arrayer-1 device (Beecher
Instruments, Sun Prairie, WI). Tumor and normal tissue
areas were identified using hematoxylin and eosin-stained
sections, with 3 representative tumor and 3 representative
normal tissue cores of 1-mm diameter taken from each
FFPE case and inserted into the recipient blocks.
Immunohistochemistry and Western blotting
The Columbia cohort were analyzed by immunohisto-
chemistry (IHC) for expression of the following proteins:
PTEN, EGFR, cytokeratins 5 and 14 (CK5/14), stathmin,
and Ki67. The NKI series TMAs were analyzed herein
for CK5/14 and stathmin by IHC and previously immu-
nostained for PTEN protein [23]. PTEN IHC was per-
formed on 4-μm FFPE whole-mount tissue sections
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using the monoclonal 138G6 PTEN antibody (Cell Sig-
naling, Danvers, MA) at 1:200 dilution for 2 h at room
temperature. Microwave antigen retrieval was accom-
plished using the Dako pH 9 solution for 20 min,
followed by automated staining using the DakoCytoma-
tion TechMate 500 staining system with manufacturer’s
recommended reagents and Dako EnVision + signal de-
tection (Dako, Carpinteria, CA). PTEN staining intensity
scores for invasive tumor and non-neoplastic cells was
evaluated and the tumors classified as PTEN-negative
(PTEN−) and PTEN-positive (PTEN+) as described pre-
viously [2]. Normal epithelial and endothelial cell stain-
ing were used as internal positive controls. EGFR IHC
was performed using antibody 31G7 (Zymed/Invitrogen,
South San Francisco, CA) at 375 ng/ml (1:40) on 4-μm
TMA sections. Slides were treated for 5 min with Dako
proteinase K and washed prior to incubating in primary
antibody for 45 min at room temperature. Anti-mouse
secondary antibody was applied for 30 min, and the signal
detected using diaminobenzidine (DAB) chromogen for
3 min followed by DAB Enhancer for 4 min (all Dako).
The slides were counterstained with Gils Hematoxylin.
EGFR staining was evaluated using a threshold of ≤10 %
positive tumor cells as EGFR-negative (EGFR−) and >10 %
positive tumor cells as EGFR-positive (EGFR+). CK5/14
IHC was performed on TMAs using an antibody cocktail
and the cases scored CK5/14-positive (CK5/14+) or CK5/
14-negative (CK5/14−) as described previously [24]. Stath-
min IHC was performed on TMAs and evaluated as previ-
ously described [25]. Ki67 mouse monoclonal antibody
Ki-S5 (Dako) was used at 1:50 on whole-mount tissue
sections. IHC was performed on a Dako autostainer, using
a Vector biotinylated secondary anti-mouse antibody
(1:200 for 30 min) and Vectastain Elite detection with
DAB (Vector Laboratories, Burlingame, CA). Sections
were counterstained with methyl green (Sigma, St. Louis,
MO). Appropriate positive and negative (staining lacking
primary antibodies) controls were used in each batch of
staining. Evaluation of Ki67 was performed by determin-
ing the percentage of positive tumor nuclei as evaluated
by the CASS 200 Image Analyzer (Becton Dickinson, San
Jose, CA). Cases were considered Ki67-positive when
≥20 % of the tumor cells showed evidence of nuclear ex-
pression. For Western blotting, the following antibodies
were used: pEGFR (Tyr1068; #3777), pAKT (Ser473;
#9271), AKT (#9272) (all Cell Signaling), EGFR (Santa
Cruz Biotechnology, Santa Cruz, CA; sc-03), and β-actin
(Sigma-Aldrich, St. Louis, MO; AC-74 #A5316).
HER2 amplification
HER2 amplification was assessed for 101 Columbia cases
using chromogenic in situ hybridization (CISH) on TMAs,
with six or more signals per cell in >50 % of cancer cells
scored as HER2-amplified (HER2+) [26]. Tumors in which
Table 1 PTEN/PI3K biomarkers in 116 unselected breast cancers
Variable n % Total
Breast tumors 116 100.0 % 116
Median age (range) 53 years (30–89)
ER+ 82 70.7 % 116
ER– 34 29.3 %
PgR+ 71 61.2 % 116
PgR– 45 38.8 %
Size <20 36 31.3 % 115
20–49 64 55.7 %
50+ 15 13.0 %
Grade 1 8 7.0 % 115
Grade 2 32 27.8 %
Grade 3 75 65.2 %
Node+ 56 53.3 % 105
Node– 49 46.7 %
HER2+ 23 20.4 % 113
HER2– 90 79.6 %
Ki67 IHC+ 35 38.0 % 92
Ki67 IHC– 57 62.0 %
S–phase ≤6 % 31 33.3 % 93
S–phase >6 %,<10 % 17 18.3 %
S–phase ≥10 % 45 48.4 %
CK5/14 IHC+ 19 17.4 % 109
CK5/14 IHC– 90 82.6 %
p53 mut 44 38.3 % 115
p53 wt 71 61.7 %
EGFR IHC+ 27 24.1 % 112
EGFR IHC– 85 75.9 %
PTEN abrogated (PTEN IHC- or mut) 26 24.3 % 107
PTEN norm 81 75.7 %
PTEN IHC– 25 23.4 % 107
PTEN IHC+ 82 76.6 %
PTEN mut 4 3.6 % 112
PTEN wt 108 96.4 %
PIK3CA mut 29 25.0 % 116
PIK3CA wt 87 75.0 %
INPP4B mRNA low 20 21.3 % 94
INPP4B mRNA norm 74 78.7 %
Any PTEN/PI3K/INPP4B 64 64.0 % 100
None PTEN/PI3K/INPP4B 36 36.0 %
Any PTEN/PI3K/INPP4B/EGFR/HER2 80 75.5 % 106
None PTEN/PI3K/INPP4B/EGFR/HER2 26 24.5 %
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the majority of cells contained 5 or fewer signals per nu-
cleus were scored HER2-non-amplified (HER2−). HER2
scores by IHC were used for 6 additional cases for which
CISH hybridization failed; HER2 IHC methods are de-
scribed in [2]. The clinical diagnostic pathology evaluation
for HER2 was utilized for another 6 cases lacking HER2
CISH and IHC data.
PCR and sequence analysis
Sequencing of PIK3CA exons 1, 2, 4, 5, 7, 9, 12, 13, 18,
and 20 for the Columbia cohort of cases has been de-
scribed previously [2]. In the present study we have per-
formed additional mutational analysis of the Columbia
cohort for PTEN and TP53. Mutational screening of
TP53 exons 2 through 11 was performed using 8 pre-
validated primer assays and direct bi-directional sequen-
cing (Agencourt Bioscience, Beverly, MA). PTEN and
TP53 sequence traces were analyzed using Mutation Sur-
veyor (Softgenetics, State College, PA) and Polyphred
(http://droog.gs.washington.edu/polyphred/), respectively.
Gene expression profiling
Gene expression profiles were generated for 95 Columiba
cases using Agilent 44 K microarrays following the manu-
facturer protocol and scanned on an Agilent Microarray
Scanner. Stratagene Universal Human Reference RNA
was used as the common control sample. Images were an-
alyzed using the Agilent Feature Extraction Software
and the raw data loaded into BASE [27] for processing.
Background-corrected intensities (mean foreground –
median background) were filtered for values with A > 0.5
(A = log10(channel1 * channel2)/2) and the data normalized
using the Lowess algorithm. Tumors were dichotomized
into INPP4 low and high categories, with low defined as
the log2 ratio <0 (20 cases) in expression as measured by
the microarray INPP4 probe A_24_P915492. The tumors
were classified into the Hu et al. [28] intrinsic molecular
subtypes (luminal A, luminal B, HER2, basal-like, or
normal-like): 301 unique gene symbols from Hu et al.
mapped to 273 gene symbols in our data. The log2 data
were averaged on gene symbol and centered across all sam-
ples, and classified into subtypes based on the best Pearson
correlation to the Hu centroids. The tumors were classified
by the PTEN-loss signature [25]: 173 unique gene symbols
from Saal et al. mapped to 143 gene symbols in the
44 K microarray data. The data were similarly averaged
and centered as above, and the PTEN-loss-signature
present or absent score calculated as described previ-
ously with a sample |score| <0.2 set as unclassified [25].
Microarray data are available from the NCBI Gene Ex-
pression Omnibus (http://www.ncbi.nlm.nih.gov/geo/)
under accession GSE74667. Previously published micro-
array data and molecular subtyping was retrieved for the
NKI series [21, 22].
Cell viability and apoptosis assays
Cells were seeded in 96-well plates at a density of 5,000-
8,000 cells in triplicates. After 24 h, cells were treated
with different concentrations of the indicated inhibitors
and incubated at 37 °C. The cells were cultured for 4 days
and then the number of viable cells was measured by
CellTiter-Glo luminescent cell viability assay according to
the manufacturer’s standard protocol (Promega). Analysis
for synergistic drug combination efficacy was carried out
using the method of Chou and Talalay [29] using Compu-
Syn 3.0.1 (ComboSyn Inc., Paramus, NJ). Combination
index (CI) values of <1 are taken to indicate synergistic
interaction between drugs, and CI values of >1 indicate
drug antagonism. To measure apoptosis, both adherent
and floating cells were harvested after drug treatment, and
the cell nuclei were stained with ethidium bromide [30].
Detection and quantitation of apoptotic cells (sub-G1
fraction) were performed by flow cytometric analysis as
described previously [18].
Animal studies
Six-week-old nu/nu athymic female mice (NCI-Frederick
Cancer Center, Frederick, MD) were maintained in pres-
surized ventilated cages. Experiments were carried out
under an IACUC approved protocol and institutional
guidelines for the proper and humane use of animals in
research were followed. MDA-MB-468 xenograft tumors
were generated by transplanting 1.0–1.5 × 107 MDA-468
cells in a 1:1 mixture of media and Matrigel (BD Biosci-
ences, San Jose, CA) into the right flank (200 μl/mouse).
After 7–10 days, the mice bearing tumors 6–7 mm in
diameter were randomized among control and the vari-
ous treated groups (5 mice/group). Gefitinib prepared as
a lactate salt (pH 5.2) was administrated orally at a dose
of 150 mg/kg/day × 5 consecutive days each week for 3
weeks. PWT-458 was freshly prepared in PBS, and
administrated by intravenous injection at a dose of
100 mg/kg/day × 5 consecutive days each week for 3
weeks. For the combination treatment, PWT-458 was
administrated 3–4 h before gefitinib treatment. The
average tumor diameter (two perpendicular axes of the
tumor were measured) was measured in control and
treated groups using a caliper. The data are expressed
as the increase or decrease in tumor volume in mm3
(volume = π/6 × [larger diameter] × [smaller diameter]2).
For Western blot experiments, animals with established
tumors were sacrificed 5 h after treatment and tumor
lysates were prepared in 2 % SDS buffer as described
previously [18].
Data visualization and statistical analysis
Hierarchical clustering of marker data and tumors were
performed in Cluster 3.0 [31] utilizing the Pearson cor-
relation distance metric (centered) and complete linkage
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algorithm and the data visualized using Java Treeview
[32]. The Pearson χ2 test was used for correlation ana-
lyses between two binary variables or between variables
with more than 2 unordered groups, and the χ2 test for
trend was used for analyses between variables with more
than 2 ordered groups. Calculations were performed
using R version 3.1.0. All tests were two-sided and a P-
value < 0.05 was used as the cut-off for decisions of stat-
istical significance.
Results
Distribution of biomarker lesions
Our unselected Columbia cohort of 116 BCs is represen-
tative of the population seen at the Herbert Irving Com-
prehensive Cancer Center (Table 1). The median age at
diagnosis was 53 (range 30 to 89), 71 % of cases were
ER-positive, 61 % progesterone receptor (PgR) positive,
31 % were <2-cm and 87 % were <5-cm. The majority of
cases were of higher grade, approximately half had S-
phase fraction >10 %, and 53 % had lymph node-positive
disease at diagnosis. Biomarker status was determined
for PTEN (mutations and immunohistochemistry
[IHC]), PIK3CA (mutations), HER2 (amplification),
EGFR (IHC), INPP4B (mRNA expression), CK5/14
(IHC), and TP53 (mutations). Thirty-eight % of cases
had deleterious mutations of TP53, in line with the ex-
pected TP53 mutation rate in BC [33]. Seventeen % were
positive for the basal cytokeratins CK5/14 (which herein
we use to define immunohistochemical BLBC; IHC-
BLBC), consistent with reported rates [34]. As shown in
Table 1, alteration of pathway members PTEN (24 %),
PIK3CA (25 %), HER2 (20 %), EGFR (24 %), and INPP4B
(21 %) was common and the rates were in accordance
with the literature [2, 35–40]. When these five markers
were combined into a ‘pathway hit’ variable (positive if
any of the 5 markers were altered), 75 % of breast tu-
mors harbored one or more alterations that contribute
to PTEN/PI3K pathway activation.
PTEN/PI3K pathway-related tumor clusters
To visualize these biomarker data we utilized unsuper-
vised hierarchical clustering. As shown in Fig. 1a, the
116 tumors were clustered into four clusters by virtue of
the intrinsic relationships between the markers ER, PgR,
PTEN, PIK3CA, HER2, EGFR, INPP4B, CK5/14, and
TP53. Cluster A, containing 22 tumors, is largely defined
by lack of ER and/or PgR hormone receptor expression
(15/22; 68 % expressed neither receptor and no case co-
expressed both receptors), EGFR-overexpression (18/22;
82 %), IHC-BLBC status (15/22; 68 %), mutated TP53 (18/
22; 82 %), and PTEN-loss (14/21; 67 %). When annotated
to additional clinicopathological data not utilized in gener-
ating the clusters (Fig. 1b), we note that this cluster con-
tained entirely histological grade 3 tumors (22/22; 100 %)
and had the highest proportion of Ki67-positive tumors
(13/17; 76 %). Ten tumors formed cluster B, which is
characterized primarily by lack of hormone receptor ex-
pression (0 %), HER2-amplification (80 %), and high histo-
logical grade (70 %). A large group of 67 tumors form
cluster C, which are characterized by being predominantly
ER-postive and PgR-postive (65/67; 97 %). Cluster C sub-
clusters are defined by loss of INPP4B (subcluster C1),
general lack of any other aberrations (C2), PIK3CA
mutation-positive without TP53 mutation (C3) or with
TP53 mutation (C5), and HER2-amplified cases with TP53
mutation (C4). Cluster D is defined by ER-postive/PgR-
negative without other aberrations (Fig. 1a).
Microarray gene expression profiling (GEX) was per-
formed to further discern biological insight into the
biomarker-defined clusters. Cluster A tumors were pre-
dominantly classified as belonging to the basal-like in-
trinsic molecular subtype (termed GEX-BLBC herein)
(16/18; 89 %), and 75 % of the tumors (15/18) were clas-
sified, using our previously described signature, as hav-
ing a gene expression pattern of PTEN-loss (Fig. 1b). In
line with expectations, 50 % of cluster B belonged to the
HER2-enriched subtype by GEX, and 50 % of cluster B
expressed the PTEN-loss-like signature. Clusters C and
D were primarily luminal subtype by GEX (75 %: 51 %
luminal A, 24 % luminal B) and only 29 % had an
expression profile of PTEN-loss. Subcluster C4 (HER2-
amplified) was predominantly HER2-enriched or luminal
B subtype (75 %). As previously described [41, 42], the
subgroups for BLBC status defined by GEX, CK5/14, or
triple-negative receptors were not completely synony-
mous (Fig. 1). Finally, across the dataset the PTEN IHC-
negative cases were predominantly classified as having
the expression signature of PTEN-loss (P = 0.019).
The differences in the distribution of Ki67 status,
tumor grade, intrinsic molecular subtypes, and presence
of the PTEN-loss signature across the main tumor clusters
A-D were significant (P = 0.0009, P = 0.0067, P < 0.0001,
P = 0.0012, respectively). However, the distribution of
lymph node status and S-phase fraction were not related
to the biomarker clusters (P = 0.2947 and P = 0.2604, re-
spectively) (Fig. 1b). We performed IHC for stathmin, a
PTEN signature gene that we have previously shown to be
upregulated in breast tumors with PI3K/PTEN pathway
activation [25]. Confirming our previous findings, stath-
min protein levels were significantly higher in tumors with
PTEN protein loss (P = 0.0015), with PTEN abrogation
(P = 0.0015), and in tumors expressing the PTEN-loss
gene expression signature (P = 0.0005) (Fig. 1b).
Associations between pathway lesions
We next wanted to evaluate the relationship of PTEN/
PI3K/INPP4B/RTK pathway lesions to each other. We
have previously reported in a series of Swedish stage II
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sporadic breast carcinomas that mutations of PIK3CA
and loss of PTEN are mutually exclusive [2]. Confirm-
ing this in our independent unselected patient cohort,
PIK3CA and PTEN loss were essentially mutually ex-
clusive with only one tumor being both PIK3CA mu-
tated and PTEN IHC-negative (P = 0.0116; Table 2).
When including PTEN mutational data only two cases
had mutant PIK3CA and abrogated PTEN (either
PTEN IHC-negative or PTEN-mutant) (P = 0.0718).
Together, this implies that there is little selective pres-
sure to activate the pathway by hitting both enzymes at
the PIP3 axis in breast tumors. Interestingly, the single
case mutated for both PTEN and PIK3CA was PTEN
IHC-positive and harbored a PTEN I28T mutation to-
gether with the PIK3CA E545K mutation. PTEN I28T
mutation, to our knowledge, has not been reported in
the literature in any tumor type and mutation at resi-
due 28 has been reported in only three times (COS-
MIC Database, http://www.sanger.ac.uk/genetics/CGP/
cosmic/). Given that this PTEN mutant was the only
mutant (out of 4) that was PTEN IHC-positive, the
functional relevance of this mutation is not clear. Intri-
guingly, more than half of the cases with loss or abro-
gation of PTEN protein expression overexpressed EGFR
(P < 0.0001 and P < 0.0001, respectively), suggesting co-
operation between EGFR and PTEN/PI3K signaling. Simi-
larly, tumors with EGFR overexpression frequently had
low INPP4B expression (P = 0.0189). No other significant
associations were noted between PTEN/PI3K pathway
alterations (Table 2).
Pathway lesions and clinicopathological variables
Given the inherent biological groups identified by un-
supervised hierarchical clustering analysis (Fig. 1), we
queried the correlation of pathway lesions to common
clinicopathological markers in BC (Table 3). Supporting
prior reports, PTEN protein loss by IHC and the PTEN
abrogated state (either PTEN IHC-negative or PTEN-
mutated) was significantly more common in ER-negative
tumors (P = 0.0007 and P = 0.0013, respectively) and
PgR-negative tumors (P = 0.0003 and P = 0.0007). PTEN
loss or abrogation was also significantly correlated to
higher grade (P = 0.0017 and P = 0.0012, respectively)
and larger tumor size (P = 0.0018 and P = 0.0005). Simi-
larly, EGFR overexpression was associated to hormone
receptor negativity (P < 0.0001) and increasing tumor
grade (P = 0.0008), but not tumor size (P = 0.2160). Sev-
enty-six % of PIK3CA mutants were ER-positive, and
although larger studies have found an association be-
tween PIK3CA mutation and ER status [2, 6], this was
not a significant enrichment in the present cohort per-
haps as a consequence of limited sample size. Interest-
ingly, PIK3CA mutations correlated with lower tumor
grade (P = 0.0265) and lower S-phase fraction (P = 0.0416)
(Table 3). This result was supported also by reduced Ki67
(P = 0.0121). Using the 5-biomarker ‘pathway hit’ variable,
97 % (33/34) of ER-negative tumors had one or more
pathway alterations compared to 65 % of ER-positive
tumors (P = 0.0004; Table 3). Similarly, 88 % of PgR-
negative tumors had one or more pathway alterations
compared to 67 % of PgR-positives (P = 0.0144; Table 3).
Fig. 1 Clustering of unselected breast tumors. a The biomarker variables ER, PgR, PIK3CA, TP53, HER2, PTEN, EGFR, and CK5/14 were used to hierarchically
cluster 116 breast tumors. Biomarker data are colored such that red = positive, black = negative, green = mutant (TP53) or lost (INPP4B, PTEN;
asterix denotes PTEN mutation), and grey = missing data. b Below the heatmap are additional clinicopathological annotations not used to
generate the clustered heatmap: Ki67, S-phase fraction (SPF), histological grade, PTEN-loss signature status, and intrinsic molecular subtype by
gene expression profilling. For each annotation, color key is shown to the right (grey = missing data). SP = signature present; SA = signature
absent; NC = not classified
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Table 2 Associations between pathway alterations
PTEN mut PTEN wt n p HER2+ HER2- n p EGFR+ EGFR- n p PIK3CA mut PIK3CA wt n p INPP4B low INPP4B high n p
PTEN IHC- 3 20 103 0.010 2 23 107 0.117 14 11 107 <0.0001 1 24 107 0.012 6 11 85 0.111
PTEN IHC+ 1 79 18 64 12 70 23 59 12 56
PTEN abrogation 2 24 107 0.098 14 12 107 <0.0001 2 24 107 0.072 6 12 85 0.155
PTEN normal 18 63 12 69 22 59 12 55
HER2+ 8 14 110 0.150 6 17 113 0.871 3 15 91 0.624
HER2- 19 69 22 68 16 57
EGFR+ 5 22 112 0.436 8 12 90 0.019
EGFR- 22 63 11 59
PIK3CA mut 4 24 94 0.281
PIK3CA wt 16 50
Footnote: Significant p-values are indicated by bolding
Abbreviations: mut mutant, wt wild-type
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Table 3 Correlation of PI3K Pathway Lesions to Other Clinicopathological Markers
ER+ ER– n P PgR+ PgR – n P p53 mut p53 wt n P CK5/14 + CK5/14 – n P Grade 1 Grade 2 Grade 3 n P
PTEN IHC– 11 14 107 0.0007 8 17 107 0.0003 15 9 106 0.006 11 13 106 <0.0001 0 2 23 106 0.002
PTEN IHC+ 65 17 59 23 26 56 7 75 8 27 46
PTEN mut 2 2 112 0.334 2 2 112 0.600 3 1 112 0.115 2 2 105 0.061 0 0 4 111 0.166
PTEN wt 78 30 68 40 39 69 15 86 8 31 68
PTEN abrogated 12 14 107 0.001 9 17 107 0.0007 16 9 106 0.003 11 14 106 <0.0001 0 2 24 106 0.0012
PTEN normal 64 17 58 23 25 56 7 74 8 27 45
HER2+ 13 10 113 0.092 13 10 113 0.548 13 10 112 0.058 3 18 108 0.740 1 7 15 112 0.806
HER2– 67 23 57 33 31 58 15 72 7 24 58
EGFR+ 4 23 112 <0.0001 5 22 112 <0.0001 19 8 111 <0.0001 15 11 109 <0.0001 0 2 25 111 0.0008
EGFR– 74 11 63 22 24 60 4 79 8 29 47
PIK3CA mut 22 7 116 0.480 21 8 116 0.153 11 18 115 0.966 4 22 109 0.753 4 10 14 115 0.027
PIK3CA wt 60 27 50 37 33 53 15 68 4 22 61
INPP4B low 10 10 94 0.012 12 8 94 0.773 10 10 93 0.292 6 13 88 0.057 3 3 14 94 0.954
INPP4B high 58 16 47 27 27 46 9 60 5 24 45
Any PTEN/PI3K/INPP4B 44 17 95 0.434 37 24 95 0.333 24 36 94 0.305 11 47 89 0.467 2 13 45 94 0.004
None PTEN/PI3K/INPP4B 27 7 24 10 10 24 4 27 5 13 16
Any PTEN/PI3K/INPP4B/
EGFR/HER2
47 33 106 0.0004 43 37 106 0.014 40 39 105 0.0004 19 56 101 0.0044 6 17 56 105 0.081
None PTEN/PI3K/INPP4B/
EGFR/HER2
25 1 21 5 3 23 0 26 2 12 12
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Table 3 Correlation of PI3K Pathway Lesions to Other Clinicopathological Markers (Continued)
<20 mm 20–49 mm 50 mm+ n P Node+ Node – n P S–phase
≤6 %
S–phase
6-10 %
S–phase
≥10 %
n P Basal-like HER2 Normal-like LumA LumB n P
PTEN IHC– 3 14 8 107 0.002 14 8 97 0.392 4 1 13 85 0.062 11 2 2 0 2 86 0.0003
PTEN IHC+ 28 47 7 40 35 24 15 28 11 6 8 31 13
PTEN mut 0 3 1 111 0.175 2 2 101 0.855 1 0 2 91 0.708 3 0 0 0 0 94 0.048
PTEN wt 35 58 14 53 44 30 16 42 20 10 10 34 17
PTEN abrogated 3 14 9 107 0.0005 15 8 97 0.291 5 1 13 85 0.135 12 2 2 0 2 86 <0.0001
PTEN normal 28 47 6 39 35 23 15 28 10 6 8 31 13
HER2+ 7 13 3 113 0.979 13 8 103 0.437 3 3 10 90 0.177 3 7 3 2 3 92 0.0003
HER2– 28 50 12 43 39 26 14 34 19 3 8 31 13
EGFR+ 6 16 5 112 0.216 13 9 102 0.583 5 3 14 89 0.112 16 3 1 0 0 91 <0.0001
EGFR– 28 47 10 42 38 25 13 29 7 6 10 32 16
PIK3CA mut 10 16 3 115 0.568 16 11 105 0.474 13 3 9 93 0.042 5 3 5 12 3 95 0.446
PIK3CA wt 26 48 12 40 38 18 14 36 18 7 6 22 14
INPP4B low 8 7 5 93 0.928 9 10 85 0.750 5 6 3 73 0.235 11 1 1 7 0 94 0.003
INPP4B high 19 47 7 34 32 20 9 30 12 9 10 26 17
Any PTEN/PI3K/INPP4B 18 34 8 94 0.561 27 27 84 0.379 20 6 26 78 0.594 14 4 6 18 9 83 0.892
None PTEN/PI3K/INPP4B 8 21 5 18 12 6 8 12 6 2 5 12 7
Any PTEN/PI3K/INPP4B/
EGFR/HER2
21 47 12 106 0.268 40 33 96 0.559 23 10 30 84 0.319 23 10 9 16 8 92 <0.0001
None PTEN/PI3K/INPP4B/
EGFR/HER2
9 15 2 11 12 4 6 11 0 0 2 16 8
Footnote: Definitions are as in Table 2
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TP53 mutation was significantly positively correlated to
PTEN/PI3K pathway alterations when analyzed as the
combined pathway hit variable (P = 0.0004), and individu-
ally to PTEN alterations (P = 0.0029) and EGFR over-
expression (P = 0.0001), but not to HER2-amplification,
PIK3CA mutations, or INPP4B loss (P = 0.0576, P = 0.9663,
and P = 0.2921, respectively) (Table 3). Of note, 3 of 4
PTEN mutants were also TP53 mutated. Consistent with
the literature (see [33] for a review), TP53 mutations were
significantly more common in ER-negative tumors com-
pared to ER-positive tumors (62 % vs. 28 %, P = 0.0008);
were prevalent in CK5/14+ basal-like tumors (61 %;
P = 0.0341); and the mutational rate increased with grade
(0 % mutated in grade 1, 28 % in grade 2, 47 % mutated in
grade 3; P = 0.0031). No significant associations to patient
outcome were found for the tumor group clusters, nor
when testing individual or aggregated pathway lesions.
This is likely due to the fact that there was a high rate of
loss to follow-up (median follow-up 2.5 years, range 0 to
12 years).
Importantly, we found loss of PTEN to be common
among IHC-BLBC (61 % vs. 16 % in non-BLBC; P < 0.0001;
Table 3). Moreover, as expected EGFR overexpression was
also significantly associated to the IHC-BLBC subtype
(79 % vs. 12 %; P < 0.0001). When utilizing the combined
pathway hit variable, all IHC-BLBC (100 %) and all
GEX-BLBC tumors (100 %) had ≥1 PTEN/PI3K pathway-
activating lesion compared to 68 % and 62 % of non-
basal-likes (P = 0.0044 and P = 0.0005).
The significant association between PTEN protein loss
and BLBC status was confirmed in the independent series
of consecutive breast cancer cases from the Netherlands
Cancer Institute (NKI). Corroborating our findings in the
Columbia cohort, CK5/14 was a good surrogate for BLBC
status in the NKI series with 22 of 25 (88 %) CK5/14-posi-
tive cases belonging to the GEX-BLBC subtype (P < 0.0001,
n = 220). Furthermore, PTEN protein loss occurred signifi-
cantly more often within the BLBC subtype whether de-
fined by microarray subtyping (23/46; 50 % of GEX-BLBC
had PTEN-loss; P = 0.0003, n = 245) or when defined by
CK5/14-positivity (15/25; 60 % of IHC-BLBC had PTEN-
loss; P < 0.0001, n = 218). To note, stathmin protein levels
were again significantly higher in tumors with PTEN pro-
tein loss (P = 0.0019, n = 237) and in tumors expressing the
PTEN-loss gene expression signature (P < 0.0001, n = 239).
Combined inhibition of PI3K and EGFR synergistically
inhibits BLBC cell growth in vitro
Based on these results, we hypothesized that monother-
apy against either the PI3K or EGFR pathway nodes in
BLBC may be ineffective due to resistance mediated by
the alternative uninhibited signaling route, and therefore
combination therapy could synergistically overcome this
resistance mechanism. We first tested this in vitro using
HCC70 BC cells, a relevant model which has high EGFR
expression, PTEN mutation, and displays the BLBC
phenotype by gene expression profiling [30]. When cells
were treated from 0.5 μM to 10 μM concentration, the
small molecule EGFR inhibitor gefitinib was marginally
growth inhibiting at low concentrations and cytostatic at
high concentrations (Additional file 1: Figure S1a). How-
ever, when combined with 5 μM or 10 μM of the PI3K
pathway inhibitor LY294002, dose-dependent synergistic
growth inhibition was seen with a combination index of
<0.4 at all dose combinations (Fig. 2a-b). The effect of
the combination treatment was accompanied by a
marked induction of apoptosis (Fig. 2c). Similar synergis-
tic effects for gefitinib plus LY294002 were seen in a
second BLBC model cell line, SUM149, which also
overexpresses EGFR and is mutant for PTEN (Fig. 2c-d;
Additional file 1: Figure S1b).
Combined inhibition of PI3K and EGFR effectively suppresses
PTEN-deficient and EGFR-overexpressing BLBC tumor growth
in vivo
The synergistic anti-proliferative and apoptotic effects of
the combination of PI3K pathway and EGFR inhibitors
in vitro suggest that targeting both PI3K and EGFR
pathways may be a rational strategy for the treatment of
BLBC. To explore the feasibility of this therapeutic strat-
egy, we tested the safety and efficacy of inhibiting PI3K
and EGFR in vivo using a mouse xenograft model with
the BLBC cell line MDA-MB-468 which has DNA amp-
lification and overexpression of EGFR as well as PTEN
loss [18, 30, 43]. Similar to the findings observed in
HCC70 and SUM149 BCLB cells (Fig. 2 and Additional
file 1: Figure S1), we have previously shown that MDA-
MB-468 cells also respond poorly to inhibition with
LY294002 or gefitinib alone but are very sensitive to
combination of these PI3K and EGFR inhibitors for a
synergistic induction of apoptosis [18]. Here, we utilized
the PI3K-inhibitor, pegylated-17-hydroxywortmannin
(PWT-458), which is completely miscible in feed water
and relatively stable in plasma [44]. Similar to our in vitro
results, administration of PWT-458 or gefitinib alone slo-
wed growth of tumors, but they still grew significantly
(Fig. 3a). In contrast, treatment with both drugs profoundly
suppressed the growth of the tumor xenografts and caused
tumor regression. In addition, chronic administration of
both PWT-458 at 100 mg/kg and gefitinib at 150 mg/kg
for 5 consecutive days each week for 3 weeks was well tol-
erated with no weight loss in the animals (Additional file 2:
Figure S2). Analysis of xenograft tumors by western blot
indicated that gefitinib markedly inhibited EGFR phos-
phorylation but had no effect on AKT phosphorylation
(Fig. 3b). By contrast, PWT-458 effectively caused reduc-
tion in AKT phosphorylation but had no effect on EGFR
phosphorylation. However, gefitinib in combination with
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PWT-458 was associated with a profound decrease in the
phosphorylation levels of both EGFR and AKT (Fig. 3b).
These data highlight the effectiveness of concomitant in-
hibition of PI3K and EGFR in BLBC.
Discussion
We show in this study that PTEN/PI3K pathway alter-
ations occur in more than half of an unselected popula-
tion of 116 human breast carcinomas. Specifically, nearly
all ER-negative breast tumors have one or more PTEN/
PI3K pathway alterations in stark contrast to the rate in
ER-positives. This result may have important clinical
implications, as, with the exception of trastuzumab
(Herceptin) for HER2-amplified BC, there are presently
no targeted therapeutic options for patients with ER-
negative disease. Our results suggest that therapies that
specifically attack the PI3K pathway could be effective in
this subtype of BC.
In addition to the previously reported high rate of
TP53 mutations among HER2-amplified [33] and EGFR-
overexpressing [45] BC, we found TP53 mutations to be
significantly associated to PTEN abrogation. This is highly
relevant in the context of recent work which demonstrated
in human cells that oncogenic PI3K pathway activation via
Fig. 2 Combined inhibition of PI3K and EGFR synergistically inhibits BLBC cell growth via induction of apoptosis. The growth of the basal-like HCC70
(a) or SUM149 (d) cells was assessed after 4 days of treatment with single agent or combination treatment with LY294002 and gefitinib at the indicated
concentrations. The results are shown as luminescence of viable cells. b Combination index plot for 5 or 10 μM LY294002 combined with 0.5, 1, 2, 4, 8,
or 10 μM gefitinib (HCC70) or 0.5, 1, 2, 4 μM gefitinib (SUM149). c Dose-dependent induction of apoptosis in HCC70 cells by gefitinib and LY294002
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targeted PTEN disruption or PIK3CA mutation resulted in
stabilization of p53 levels and induction of p53-mediated
cellular senescence [46]. It was concluded from this in vitro
data that loss of PTEN or mutation of PIK3CA could elicit
selective pressure on tumors to inactivate TP53 [46]. Our
result supports this hypothesis in human breast tumors
with respect to PTEN and p53, and further corroborates
the cooperative nature between PTEN lesions and p53 in-
activation that has also been observed in mouse models
[47]. Moreover, our results are consistent with the models
proposed relating the p53 stress response pathway to the
PTEN/PI3K growth pathway [48]. Of 25 BCs with abroga-
tion of PTEN and with TP53 mutational data, we found 16
cases (64 %) with coincident mutation of TP53, including 3
cases with deleterious mutations to both genes. Therefore,
our results demonstrate that the PTEN and p53 tumor
suppressors are frequently inactivated in the same individ-
ual breast tumors.
Interestingly, PIK3CA mutations were significantly as-
sociated with lower tumor grade, lower S-phase fraction,
and reduced Ki67 staining. This may indicate that, in
vivo, PIK3CA mutation is a less potent driver of cell pro-
liferation than, for example, PTEN alteration. The asso-
ciation of PIK3CA mutations to markers of favorable
prognosis and to good outcome are consistent with
other recent reports [49–51]. We previously reported
that PIK3CA mutations were positively associated to ER,
lymph node status, and HER2 status [2]. Our present
study finds similar trends, however the associations were
not significant may be due to the fact that the present
study analyzed fewer cases compared to our prior report.
We found reduced expression of INPP4B in ER-negative
breast tumors as well as occurring most frequently in
BLBC, consistent with prior reports [6, 9, 10].
All cases in our identified cluster A had one or more
PTEN/PI3K pathway activating lesions, and this cluster
closely corresponds to the basal-like subtype of BC as
defined by either CK5/14 positive staining or by GEX-
based intrinsic molecular subtyping. Our tumor marker
profiling informed a therapeutic strategy for co-targeting
Fig. 3 Combination of PI3K and EGFR inhibitors markedly suppresses PTEN-deficient and EGFR-overexpressing BLBC tumor growth in vivo. a Mice
with established MDA-MB-468 xenograft tumors were treated with PWT-458 (100 mg/kg 5 times/week), gefitinib (150 mg/kg five times/week), combination
of both drugs, or vehicle control, and tumor size was measured by caliper two times per week. The results are presented as the mean tumor volume ±
S.E.M. (n= 5 mice/group). b Representative tumors from mice in (a) were lysed 5 h after the final treatment with the indicated drugs. Tumor lysates were
subjected to Western blot analysis for the indicated proteins
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the EGFR and PTEN/PI3K nodes. This hypothesis was
tested in vitro and in vivo and we show that cluster A-
type BLBC tumors are sensitive to the combination the-
rapy with the EGFR and PTEN/PI3K pathway inhibitors.
Moreover, our data suggests that it could be clinically
feasible to identify such patients using IHC panels or by
gene expression profiling. It is interesting how PTEN/
PI3K pathway lesions and our identified tumor clusters
may relate to the other molecular subtypes. For example,
our cluster C2/C3 corresponded most closely to the
luminal A subtype, with prominent hormone receptor
expression, a low TP53 mutation rate, and reduced pro-
liferation. The C2 cluster also contained no PIK3CA
mutants, thus one would hypothesize that cases with this
profile would respond best to selective ER modulators
such as tamoxifen or to aromatase inhibitors [52–54].
Our clusters B and C4 correspond closely to the HER2
subtype, and most of these tumors have intact PTEN
and are PIK3CA wild-type, making them ideal for
traztuzumab-containing regimens [15, 17]. Subcluster
C5 is ER+ with TP53 mutation and has an overlap with
the luminal B class. Given that PI3K pathway activation
has been implicated in tamoxifen resistance [52–54] and
TP53 mutations in resistance to polychemotherapy with
cyclophosphamide, methotrexate, and 5-fluorouracil
[55], we would hypothesize that tumors with a pathway
profile like cluster C5 may require more intensive regi-
mens than standard treatment. These hypotheses require
further evaluation in appropriate models and patient
material.
We found that BLBC tumors frequently have coinci-
dent EGFR-overexpression and loss of PTEN, which
may implicate their selective advantage for maintaining
BLBC transformation and contributing to the aggressive
BLBC characteristics. We have previously found that in
MDA-MB-468 BLBC cells with coexistent EGFR-
overexpression and PTEN loss, inhibition of EGFR with
gefitinib has no effect on PI3K/AKT signaling but effect-
ively suppresses MAPK signaling [18]. Thus, PTEN-
deficient MDA-MB-468 cells proliferate and survive in
an EGFR-independent manner. However, restoration of
PTEN or inhibition of PI3K with LY294002 causes these
cells to depend on EGFR/MAPK signaling pathway for
survival, whereas combined inhibition of both PI3K/
AKT and EGFR/MAPK signaling pathways synergistic-
ally induces apoptosis. Mechanistically, we have identi-
fied the BAD protein as a switch that integrates the
antiapoptotic effects of the PI3K/AKT and EGFR/MAPK
pathways [18]. Each pathway is responsible for phosphor-
ylation of BAD at a distinct site. Genetic induction of
PTEN expression in combination of with the EGFR inhibi-
tor gefitinib synergistically suppresses PTEN-deficient and
EGFR-overexpressing BLBC tumor growth and causes
tumor regression [18]. The current study demonstrates
effective synergy in vitro and in vivo using combination of
pharmacological inhibitors targeting both EGFR and PI3K
for the treatment of BLBC with concurrent PTEN loss
and EGFR overexpression. We cannot rule out that off-
target effects of LY294002 may have contributed to the
synergistic effects observed when combined with gefitinib.
Moreover, PMT-458 is a pan-PI3K inhibitor. To further
delineate the signaling, these studies can be improved
upon by the use of more specific inhibitors. Nevertheless,
together our studies provide a heuristic model for under-
standing pathway interactions and suggest that combin-
ation therapy with EGFR/MAPK and PI3K/AKT pathway
inhibitors is a rational strategy for BLBC treatment and
deserves further pre-clinical/clinical testing. Our results
parallel the situation seen in glioblastoma multiforme in
which overexpression or amplification of EGFR and its
variant, EGFRvIII, is commonly associated with PTEN
deletion or mutation. This suggests that the coexistence of
EGFR activation with PTEN loss may be a common para-
digm in cancer that could potentially be exploited. This
hypothesis should be extended beyond breast and brain
cancers. For example, EGFR and PTEN appear to be
involved in the pathogenesis of lung adenocarcinoma,
however the prevalence of both lesions is not well studied.
If loss of PTEN is frequent among EGFR-positive cancer,
then this may be a contributing factor to the significant
resistance to EGFR inhibitors seen in the clinic [16] and
further stresses the potential importance of combination
therapies against both EGFR/MAPK and PTEN/PI3K/
AKT signaling pathways. Interestingly, inhibition of AKT
signaling appears to activate some RTKs via de-repression
of RTK expression and increased RTK phosphorylation,
including that for EGFR in some tumor models [56].
Together, our data suggest that a promising strategy may
be to co-target RTKs such as EGFR when targeting the
PI3K/AKT pathway, and vice versa.
In summary, we have revealed novel relationships
between PTEN/PI3K pathway lesions and of these lesions
to the BC subtypes. Furthermore, we show that aberrant
PTEN/PI3K signaling is closely correlated to mutation of
TP53. Our biomarker and therapy results have important
and obvious clinical implications for stratifying patients
and designing clinical trials that target the PTEN/PI3K
pathway as well as the EGFR/HER2 receptors and MAPK
pathway. Finally, the fact that the majority of BCs have
oncogenic PTEN/PI3K pathway lesions associated with
the worst prognosis highlights the enormous need and
potential benefit for targeting this pathway using recently
developed PI3K and AKT inhibitors.
Conclusions
We have performed a comprehensive molecular
characterization of unselected breast cancers and show a
high rate of PTEN/PI3K pathway-related alterations in
She et al. BMC Cancer  (2016) 16:587 Page 13 of 16
ER-negative breast cancer, an in particular show that
basal-like breast cancers often display concomitant
overexpression of EGFR and loss PTEN, the negative
regulator of PI3K. We evaluated a combination therapy
co-targeting EGFR and PI3K in models of basal-like
breast cancer in vitro and demonstrate synergistic anti-
cancer effects that shrinks tumors in vivo, with greater
efficacy than either monotherapy. Our results support the
clinical evaluation of combining EGFR/MAPK and PI3K/
AKT pathway inhibitors for the treatment of BLBC.
Additional files
Additional file 1: Figure S1. HCC70 (A) or SUM149 (B) cells were
treated with single-agent gefitinib (left) or combination treatment with 5
μM LY294002 plus gefitinib at the concentrations indicated and cell pro-
liferation measured over 4 days. (PDF 217 kb)
Additional file 2: Figure S2. Chronic treatment with gefitinib and PWT-
458, alone or in combination, does not cause eight loss in mice. Mice
bearing MDA-MB-468 xenograft tumors were treated with PWT-458
(100 mg/kg five imes/week), gefitinib (150 mg/kg five times/week),
combination of both drugs, or vehicle control. The mouse body weight
was measured in control and treated groups using a weighing scale. The
results represent the mean body weight ± S.E.M. (n = 5 mice per group).
(PDF 880 kb)
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